Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2017 Nov 22;81(1):171–178. doi: 10.1007/s00280-017-3484-5

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Population pharmacokinetic final model. Individual predictions were compared to observed concentrations in the study for: A. Liposomal cytarabine, B. Liposomal daunorubicin, C. Uracil arabinoside (araU, cytarabine metabolite), and D. Daunorubicinol (daunoU, daunorubicin metabolite). Open black circles represent the maximum tolerable dose of 101 units/m2 while other doses are represented by solid gray circles. One subject made minimal daunoU metabolite (ID: 2013) and was denoted by gray triangles.